# A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

> **NCT01738555** · PHASE2 · WITHDRAWN · sponsor: **RFS Pharma, LLC**

## Conditions studied

- Human Immunodeficiency Virus Infection

## Interventions

- **DRUG:** amdoxovir 300 mg bid
- **DRUG:** amdoxovir 500 mg bid

## Key facts

- **NCT ID:** NCT01738555
- **Lead sponsor:** RFS Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-04
- **Primary completion:** 2014-08
- **Final completion:** 2014-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01738555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01738555, "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01738555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*